These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 9622209)

  • 1. Clinical experience with recombinant factor VIIa.
    Lusher J; Ingerslev J; Roberts H; Hedner U
    Blood Coagul Fibrinolysis; 1998 Mar; 9(2):119-28. PubMed ID: 9622209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
    Parameswaran R; Shapiro AD; Gill JC; Kessler CM;
    Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008).
    Neufeld EJ; Kessler CM; Gill JC; Wilke CT; Cooper DL;
    Haemophilia; 2011 Jul; 17(4):650-6. PubMed ID: 21299750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.
    Birschmann I; Klamroth R; Eichler H; Schenk J; Kirchmaier CM; Halimeh S
    Haemophilia; 2013 Sep; 19(5):679-85. PubMed ID: 23647644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant factor VIIa in joint and muscle bleeding episodes.
    Bech RM
    Haemostasis; 1996; 26 Suppl 1():135-8. PubMed ID: 8904188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and effectiveness of room temperature stable recombinant factor VIIa in patients with haemophilia A or B and inhibitors: Results of a multinational, prospective, observational study.
    Kavakli K; Demartis F; Karimi M; Eshghi P; Neme D; Chambost H; Sommer L; Zak M; Benson G
    Haemophilia; 2017 Jul; 23(4):575-582. PubMed ID: 28440004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ten-year experience of recombinant activated factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in Japan.
    Takedani H; Shima M; Horikoshi Y; Koyama T; Fukutake K; Kuwahara M; Ishiguro N
    Haemophilia; 2015 May; 21(3):374-379. PubMed ID: 25521821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Relevance of a single dose of 270 microg/kg recombinant factor VIIa for the treatment of patients with haemophilia and inhibitors - Recommendations from the GTH experts].
    Auerswald G; Muntean W; Kemkes-Matthes B; Klamroth R; Krause M; Kurnik K; Oldenburg J; Pabinger-Fasching I; Schramm W; Zimmermann R; Zotz RB
    Hamostaseologie; 2009 May; 29(2):197-203. PubMed ID: 19404511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
    Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
    Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.
    Shapiro AD; Neufeld EJ; Blanchette V; Salaj P; Gut RZ; Cooper DL
    Haemophilia; 2014 Jan; 20(1):e23-31. PubMed ID: 24354484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall experience with NovoSeven.
    Négrier C; Lienhart A
    Blood Coagul Fibrinolysis; 2000 Apr; 11 Suppl 1():S19-24. PubMed ID: 10850559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of acute bleeding in acquired haemophilia A with recombinant activated factor VII: analysis of 10-year Japanese postmarketing surveillance data.
    Amano K; Seita I; Higasa S; Sawada A; Kuwahara M; Shima M
    Haemophilia; 2017 Jan; 23(1):50-58. PubMed ID: 27457022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors.
    Abshire T; Kenet G
    Haemophilia; 2008 Sep; 14(5):898-902. PubMed ID: 18684126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgical experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX.
    Valentino LA; Cooper DL; Goldstein B
    Haemophilia; 2011 Jul; 17(4):579-89. PubMed ID: 21294815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors.
    Qi X; Zhao Y; Li K; Fan L; Hua B
    Blood Coagul Fibrinolysis; 2014 Oct; 25(7):754-60. PubMed ID: 24806320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a phase I study.
    Macik BG; Lindley CM; Lusher J; Sawyer WT; Bloom AL; Harrison JF; Baird-Cox K; Birch K; Glazer S; Roberts HR
    Blood Coagul Fibrinolysis; 1993 Aug; 4(4):521-7. PubMed ID: 8218848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding.
    Wang M; Lawrence JB; Quon DV; Ducore J; Simpson ML; Boggio LN; Mitchell IS; Yuan G; Alexander WA; Schved JF
    Haemophilia; 2017 Nov; 23(6):832-843. PubMed ID: 28776894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial.
    Pruthi RK; Mathew P; Valentino LA; Sumner MJ; Seremetis S; Hoots WK;
    Thromb Haemost; 2007 Oct; 98(4):726-32. PubMed ID: 17938794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label.
    Croteau SE; Nakar C; Neufeld EJ; Shapiro A; Cooper DL
    Pediatr Blood Cancer; 2016 Oct; 63(10):1822-8. PubMed ID: 27232114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Major orthopaedic surgeries for haemophilia with inhibitors using rFVIIa.
    Takedani H; Kawahara H; Kajiwara M
    Haemophilia; 2010 Mar; 16(2):290-5. PubMed ID: 19925628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.